Ulcerative Colitis Press Releases

Despite its strong efficacy, Remicade is facing increased competition from newer drugs and the prospect of pipeline drugs set to launch in the coming years.

Among branded ulcerative colitis treatments, 84% of US gastroenterologists expect Zeposia to see an increase in prescription volume over the next 12 months, according to new research on the ulcerative colitis marketplace published by Vivisum Partners.

New research into ulcerative colitis pipeline drugs found that US gastroenterologists who treat irritable bowel disease (IBD) have low awareness of some developing therapies.

Newly published research found that several new ulcerative colitis drugs currently in development are providing excitement among gastroenterologists eager to add additional medicines to their current treatment options.